The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab - Concepedia

Concepedia

Publication | Open Access

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

DOI Full Paper Access

45

Citations

31

References

2021

Year

Edoardo Lenci, Luca Cantini, Federica Pecci, Valeria Cognigni, Veronica Agostinelli, Giulia Mentrasti, Alessio Lupi, Nicoletta Ranallo, Francesco Paoloni, Silvia Rinaldi,

Journal of Clinical Medicine

Abstract

Our data shown that GRImT1 and GRImΔ are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients treated with pembrolizumab and might represent useful biomarkers to drive clinical decisions in this setting.

References

	Year	Citations

Page 1